Outcome of very low birth weights (VLBW) babies and economic burden of Intensive care on families of VLBW (<1250 g) babies during hospital stay
Implementing Organization
All India Institute of Medical Sciences
Principal Investigator
Dr. Neeta Singh
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. Ramesh Agarwal
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. V. Sreenivas
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. J. B. Sharma
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. Alka Kriplani
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. Sunesh Kumar
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. Rajesh Khadgawat
Professor
|
All India Institute of Medical Sciences
CO-Principal Investigator
Dr. Alka Mohan Chutani
Professor
|
All India Institute of Medical Sciences
Project Overview
The prevalence of both Diabetes mellitus and Gestational diabetes mellitus(GDM) is increasing worldwide. If left untreated, it adversely affects the mother and fetus.Insulin is regarded as the gold standard treatment forachieving glycemic controls in pregnancy. Oral hypoglycemic agents including Metformin is still not approved by FDA to be used in pregnancy.Recently, various investigators evaluated the role of Metformin in GDM and concluded that Metformin gives comparable results for achieving adequate glycemic control and optimum perinatal outcome when compared with insulin.With this background, we conducted this randomized control trial to compare the safety and efficacy of Metformin and subcutaneous insulin in Asian Indian women with gestational diabetes mellitus